Liberum Capital reaffirmed their buy rating on shares of Shield Therapeutics PLC (LON:STX) in a research note issued to investors on Tuesday morning. The firm currently has a GBX 245 ($3.22) target price on the stock.
Other analysts have also issued research reports about the stock. FinnCap lowered their price target on shares of Shield Therapeutics PLC from GBX 270 ($3.55) to GBX 265 ($3.48) and set a buy rating on the stock in a research report on Friday, September 22nd. Peel Hunt reissued a buy rating and issued a GBX 220 ($2.89) price target on shares of Shield Therapeutics PLC in a research report on Wednesday, September 20th.
WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2956782/shield-therapeutics-plcs-stx-buy-rating-reiterated-at-liberum-capital-2.html.
Shield Therapeutics PLC Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.